ClinicalTrials.gg
CompletedNCT05405543Updated Jan 13, 2023

A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants

A Phase 1 interventional study of MYK-224 and Placebo in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-13.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effects of both single and multiple dose drug levels of MYK-224 in healthy adult Japanese participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • MYK-224
  • Healthy Participants of Japanese Ethnicity
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy as determined by medical history, physical examination, vital signs,12-lead and routine laboratory assessments
  • Must have documented (LVEF) ≥60% (2D biplane Simpson's Method) at screening as determined by the echocardiographic core laboratory.

Exclusion criteria

Exclusion Criteria:

  • Any acute or chronic medical illness
  • History of heart disease

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: MYK-224 · Other: Placebo

  • Experimental
    Arm 2

    Drug: MYK-224 · Other: Placebo

  • Experimental
    Arm 3

    Drug: MYK-224 · Other: Placebo

  • Experimental
    Arm 4

    Drug: MYK-224 · Other: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986435

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 72 days

  2. Time of maximum observed concentration (Tmax)

    Time frame: Up to 72 days

  3. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])

    Time frame: Up to 72 days

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 130 days

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 130 days

  3. Number of participants with adverse events leading to discontinuation

    Time frame: Up to 130 days

  4. Number of participants with vital sign abnormalities

    Time frame: Up to 72 days

  5. Number of participants with physical exam abnormalities

    Time frame: Up to 72 days

  6. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 72 days

  7. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 72 days

  8. Measurement of left ventricular ejection fraction (LVEF)

    Time frame: Up to 72 days

  9. Measurement of left ventricular outflow tract velocity time integral (LVOT-VTI)

    Time frame: Up to 72 days

  10. Measurement of left ventricular fractional shortening (LVFS)

    Time frame: Up to 72 days

  11. Measurement of left ventricular global longitudinal strain (LV GLS)

    Time frame: Up to 72 days

  12. Measurement of left ventricle stroke volume (LVSV)

    Time frame: Up to 72 days

  13. Measurement of lateral and septal early diastolic mitral annular velocity (e')

    Time frame: Up to 72 days

  14. Measurement of early diastolic mitral inflow velocity to early diastolic mitral annular velocity (E/e')

    Time frame: Up to 72 days

  15. Measurement of early diastolic mitral inflow velocity to late diastolic mitral inflow velocity ratio (E/A ratio)

    Time frame: Up to 72 days

  16. Measurement of left ventricular (LV) mass index

    Time frame: Up to 72 days

  17. Measurement of left atrial volume index

    Time frame: Up to 72 days

  18. Measurement of interventricular septal thickness

    Time frame: Up to 72 days

  19. Measurement of posterior wall thickness

    Time frame: Up to 72 days

  20. Measurement of LV end diastolic volume

    Time frame: Up to 72 days

  21. Measurement of LV end diastolic volume index

    Time frame: Up to 72 days

  22. Measurement of LV end systolic volume

    Time frame: Up to 72 days

  23. Measurement of LV end systolic volume index

    Time frame: Up to 72 days

  24. Relative bioavailability of test formulation compared to the reference formulation based on Cmax

    Time frame: Up to 72 days

  25. Relative bioavailability of test formulation compared to the reference formulation based on AUC(0-T)

    Time frame: Up to 72 days

  26. Relative bioavailability of test forumulation compared to the reference formulation based on area under the concentration-time curve from time zero extrapolated to infinite time AUC(INF)

    Time frame: Up to 72 days

07

Study locations

1 site
  • Local Institution - 0001
    Anaheim, California 92801, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Nov 2022, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2022
First posted
Jun 6, 2022
StartActual
Jul 12, 2022
Primary completionActual
Nov 16, 2022
CompletionActual
Dec 9, 2022
Last update
Jan 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05405543
Responsible party
Sponsor
First posted
Jun 6, 2022
Start date
Jul 12, 2022
Primary completion
Nov 16, 2022
Completion
Dec 9, 2022
Last update
Jan 13, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delocamten

Start the discussion